

November 1, 2023

Products Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that our **Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL**, and **Acyclovir Sodium Injection 50 mg/mL SD Vial 20 mL** will be placed on allocation effective **November 1, 2023**. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Date
02236926	C302510	919937	176826	Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL	100% Allocation Nov. 1, 2023
02236926	C302520	919949	177071	Acyclovir Sodium Injection 50 mg/mL SD Vial 20 mL	100% Allocation Nov. 1, 2023

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



Joseph Le
Senior Manager, Commercial Operations & Analytics
joseph.le@fresenius-kabi.com